Hormonal

Pharmacological inhibition of de novo ceramide synthesis using myriocin reduces hepatic steatosis, atherosclerosis, and insulin resistance in diet-induced NAFLD models by normalizing ApoB production and enhancing HDL turnover.

This research suggests that high levels of ceramides, often elevated in fatty liver disease, drive cardiovascular risk by increasing bad cholesterol production (ApoB) and slowing down good cholesterol clearance (HDL). While myriocin is not a consumer supplement, the mechanism implies that dietary strategies reducing saturated fat intake and improving insulin sensitivity may lower ceramide levels, thereby protecting against liver and heart disease.